Curaleaf Intl secures regulatory approval for handheld liquid inhalation device

Curaleaf (CURLF) International, part of Curaleaf Holdings, in collaboration with Jupiter Research, a subsidiary of TILT Holdings, has secured regulatory approval for the first handheld liquid inhalation device designed for precise medical cannabis administration. This EU medical device certification paves the way for improved patient options and a new era of innovation in medical cannabis delivery. The liquid inhalation device is now certified as a Class IIa medical device, meeting rigorous European regulatory standards. The device includes a magnetic snap-in cartridge and a rechargeable power supply, engineered to provide a consistent and controlled cannabinoid delivery. A comprehensive technical file and full EU Declaration of Conformity were assessed and approved by a recognised EU Notified Body, validating the device’s quality, safety, and clinical robustness. EU certification supports deployment in multiple global markets and once commercialised, will enable healthcare professionals to recommend the device offered by Curaleaf International in countries including European countries, the UK, Canada, and regions across Australasia.